Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Clin Cancer Res. 2018 Oct 29;25(6):1774–1785. doi: 10.1158/1078-0432.CCR-18-1871

Figure 2: Characterization of 64Cu-FN3hPD-L1 radiotracer syntheses.

Figure 2:

A: Radio- high-performance liquid chromatography (HPLC) trace showed >95% purity (area under the curve) of 64Cu-FN3hPD-L1. B: Binding assay showing that the immunoreactivity of the 64Cu-FN3hPD-L1 for CT26/hPD-L1 cells was 85±2.4%.